Investigating how DNA damage response pathways can be targeted for cancer therapy
Exploring DNA damage response pathways as targets for cancer therapy
This study is looking at how problems with the body's ability to fix DNA can lead to cancer, and it aims to find new ways to treat patients, especially those with certain genetic changes like BRCA1/2, by using advanced techniques to improve current treatments and develop new ones.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Tx Md Anderson Can Ctr NIH-funded |
| Lab location | 1 site (Houston, United States) |
| Project ID | NIH-10898051 on NIH RePORTER |
What this research studies
This research focuses on understanding how defects in DNA damage response (DDR) pathways contribute to cancer development and how these pathways can be targeted for treatment. By studying essential DDR genes and proteins, the project aims to uncover their roles in cell proliferation and DNA repair both in laboratory settings and in living organisms. The research will utilize advanced techniques, including CRISPR screens, to explore new therapeutic strategies that could improve cancer treatment outcomes for patients with specific genetic mutations, such as BRCA1/2. Ultimately, the goal is to enhance the effectiveness of existing therapies and develop new ones based on the insights gained from these studies.
Who could benefit from this research
Good fit: Ideal candidates for this research are cancer patients with BRCA1/2 mutations or those with tumors exhibiting DNA damage response deficiencies.
Not a fit: Patients without BRCA mutations or those whose cancers do not involve DNA damage response pathways may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective cancer therapies that specifically target the underlying genetic defects in tumors.
How similar studies have performed: Previous research has shown success in targeting DNA damage response pathways, particularly with the approval of PARP inhibitors for BRCA-related cancers, indicating a promising avenue for further exploration.
Where this research is happening
Houston, United States
- University of Tx Md Anderson Can Ctr — Houston, United States (Active)
Researchers
- Principal investigator: Chen, Junjie — University of Tx Md Anderson Can Ctr
- Study coordinator: Chen, Junjie
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.